Proton Magnetic Resonance Spectroscopic Method for Determination of Phenylbutazone and Oxyphenbutazone in Tablets

Abstract

A simple, specific, and rapid 'H nuclear magnetic resonance spectroscopic method for the assay of phenylbutazone and oxyphenbutazone is described. Spectra are recorded in CDC13 containing 1,3- dichloro-5-nitrobenzene as an internal standard. The aromatic proton resonances for the standard, at 57.7 and 8.2, are well separated from those of phenylbutazone and oxyphenbutazone, which are in the region of 56.5-7.3 ppm. Average percent recoveries of phenylbutazone and oxyphenbutazone were 98.9 and 98.6 with standard deviations of 0.6 and 0.7, respectively. Commercial formulations were analyzed and the results obtained by the proposed method closely agreed with those found by the British Pharmacopoeia method

Electrochemical Sensing of Phenylbutazone using Multi-Walled Carbon Nanotube Paste Electrode in Pharmaceutical and Biological Fluids

“…The most common side effects of PBZ involves the gastrointestinal system. For the determination of PBZ, several analytical methods were reported, including high-performance liquid chromatography, [14][15][16][17] Direct injection HPLC method, 18,19 Proton magnetic resonance spectroscopic, 20,21 and gas chromatography-mass spectrometry. [22][23][24] However, the main issues with using such approaches, are the building up of detectors, time-consuming extraction, usage of costly instruments and separation practices.…”